University of California, San Diego (UCSD)- Moores Cancer Center

La Jolla, California 92093-1503

4 studies enrolling now · 21 studies all time

What they study most

Acute GVHD, Acute-graft-versus-host Disease, Advanced Cholangiocarcinoma, Advanced Solid Tumor, Advanced Solid Tumors, B-cell Malignancy, Bladder Cancer, CLL, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Cholangiocarcinoma, Chronic Lymphocytic Leukemia

Studies at this site

• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting now
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — Recruiting now
• A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer — Stopped early
• Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant — Completed
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease — Completed
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) — Stopped early
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer — Completed
• CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) — Completed
• A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC — Completed
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma — Stopped early
• A Study of ICP-192 in Patients With Advanced Solid Tumors — Status unconfirmed
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma — Stopped early
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib — Stopped early